| Log in

Hospira To Buy Orchid Chemicals’ Injectable Business For $400M

15 December, 2009

US based Hospira Inc said on Tuesday that it would buy Orchid Chemicals & Pharmaceuticals Ltd’s  generic injectable drug business for $400 million in a deal that will expand its global reach and position as the market leader.

The deal includes acquisition of Orchid’s antibiotics manufacturing complex and pharmaceutical research and development facility in Chennai, India, as well as its generic injectable product portfolio and pipeline, Hospira said.

The companies also signed a long-term exclusive agreement for Orchid to supply active pharmaceutical ingredients for the business Hospira is acquiring.

Hospira expects the transaction, which the boards of both companies have unanimously approved, to be neutral to its 2010 earnings per share, excluding the impact of transaction-related expenses.

Hospira, which is based in suburban Chicago, owns about 23 percent of the roughly $11 billion global generic injectables market — more than twice the share of its closest rivals.

In a September interview with Reuters, Hospira Chief Executive Officer Chris Begley said the company was eyeing small deals that would expand the generic injectables business and its geographic footprint. Tuesday’s announcement, which gives Hospira a presence in India and a platform for future growth there, helps achieve both goals.

“This acquisition aligns perfectly with Hospira’s strategy to improve our margins and cash flow, by lowering our cost position for a key product line, and to invest for growth, by expanding our presence globally and reinforcing our leadership position in generic injectables,” Hospira Chief Operating Officer Terry Kearney said in a statement.

Hospira shares were up 76 cents, or 1.6 percent, at $49.73 in midday trading on the New York

 


Leave Your Comment
Orchid Pharma sells penicillin & penem API biz to Hospira for $200M

Orchid Pharma sells penicillin & penem API biz to Hospira for $200M

Bhawna Gupta 5 years ago
Chennai-based global pharma major Orchid Chemicals & Pharmaceuticals Ltd has...
China’s Fosun bids for KKR-backed Gland Pharma

China’s Fosun bids for KKR-backed Gland Pharma

Joseph Rai 2 years ago
Shanghai Fosun Pharmaceutical (Group) Co Ltd said on Monday it has made a non...
Pfizer front runner to clinch Strides Arcolab’s specialty biz for $1.7B

Pfizer front runner to clinch Strides Arcolab’s specialty biz for $1.7B

Sneha Shah 5 years ago
Global pharmaceutical manufacturer Pfizer is in advanced talks with Strides...
No Comments

Hospira To Buy Orchid Chemicals’ Injectable Business For $400M

Powered by WordPress.com VIP